SCHEMBL22923237

SCHEMBL22923237

CCCCCCC[C@H](CCCCN)CCCCCC

nearest known ligand 0.68

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 9/20 0.68
ALDH1A1 P00352 2/20 0.68
MEN1 O00255 1/20 0.68
KMT2A Q03164 1/20 0.68
TSHR P16473 1/20 0.68
EPHX1 P07099 1/20 0.68
LMNA P02545 1/20 0.54
SPHK1 Q9NYA1 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
GNAI3 P08754 1/20 0.47
GNAO1 P09471 1/20 0.47
GNAI1 P63096 1/20 0.47
OPRM1 P35372 1/20 0.46
CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3614598 1.00 DNM1 (0.68) DNM1ALDH1A1MEN1KMT2ATSHR
SCHEMBL8309033 1.00 DNM1 (0.68) DNM1ALDH1A1MEN1KMT2ATSHR
SCHEMBL22923343 1.00 DNM1 (0.68) DNM1ALDH1A1MEN1KMT2ATSHR
SCHEMBL21891269 1.00 DNM1 (0.68) DNM1ALDH1A1MEN1KMT2ATSHR
SCHEMBL24522348 1.00 DNM1 (0.68) DNM1ALDH1A1MEN1KMT2ATSHR
SCHEMBL22618484 1.00 DNM1 (0.68) DNM1ALDH1A1MEN1KMT2ATSHR
SCHEMBL24294234 1.00 DNM1 (0.68) DNM1ALDH1A1MEN1KMT2ATSHR
SCHEMBL21984825 1.00 DNM1 (0.68) DNM1ALDH1A1MEN1KMT2ATSHR
SCHEMBL24969585 1.00 DNM1 (0.68) DNM1ALDH1A1MEN1KMT2ATSHR
SCHEMBL9501455 1.00 DNM1 (0.68) DNM1ALDH1A1MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11273149-B2 Compositions and methods for the treatment of amyotrophic lateral sclerosis, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, and multiple system atrophy STEALTH BIOTHERAPEUTICS INC. (US) 2022-03-15 US disclosed
US-20210023062-A1 Compositions and Methods for the Treatment of Amyotrophic Lateral Sclerosis, Parkinson's Disease, Parkinson's Disease with Dementia, Dementia with Lewy Bodies, and Multiple System Atrophy STEALTH BIOTHERAPEUTICS INC. 2021-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11273149-B2 Compositions and methods for the treatment of amyotrophic lateral sclerosis, Parkinson's disease, Parkinson's disease with dementia, dementia with Lewy bodies, and multiple system atrophy NLN, TARDBP, PARK7 DNM1 57/4885ALDH1A1 4559/4885MEN1 4548/4885
US-20210023062-A1 Compositions and Methods for the Treatment of Amyotrophic Lateral Sclerosis, Parkinson's Disease, Parkinson's Disease with Dementia, Dementia with Lewy Bodies, and Multiple System Atrophy NLN, TARDBP, PARK7 DNM1 57/4885ALDH1A1 4559/4885MEN1 4548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.